Stockscreener 앱 받기
5.20
0.39%
0.02
시간 외 거래:
29.72
24.52
+471.54%
전일 마감가:
$5.18
열려 있는:
$5.17
하루 거래량:
897.59K
Relative Volume:
0.55
시가총액:
$545.93M
수익:
-
순이익/손실:
$-58.88M
주가수익비율:
-4.6746
EPS:
-1.1124
순현금흐름:
$-42.79M
1주 성능:
+4.00%
1개월 성능:
-22.27%
6개월 성능:
+26.83%
1년 성능:
+704.08%
1일 변동 폭
$5.09
$5.36
1주일 범위
$4.85
$5.435
52주 변동 폭
$0.55
$8.00
Relmada Therapeutics Inc Stock (RLMD) Company Profile
명칭
Relmada Therapeutics Inc
전화
646 876 3459
주소
2222 PONCE DE LEON BLVD. 3RD FLOOR, CORAL GABLES, NY
Compare RLMD vs PSNYW, GOODO, SHMD, DWLD, QQQE
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
| 3.03 | 0 | 0 | 0 | 0 | 0.00 | |
PSNYW
Polestar Automotive Holding Uk
|
2.5899 | 404.28M | 2.07B | -1.42B | -1.37B | -0.6765 |
GOODO
Gladstone Commercial Corporation
|
20.44 | 372.90M | 0 | 0 | 0 | 0.00 |
SHMD
Schmid Group N V
|
4.29 | 270.26M | 52.15M | -21.46M | 0 | -0.4675 |
DWLD
Davis Select Worldwide ETF
|
47.45 | 0 | 0 | 0 | 0 | 0.00 |
QQQE
Direxion NASDAQ-100 Equal Weigh
|
116.30 | 0 | 0 | 0 | 0 | 0.00 |
Relmada Therapeutics Inc Stock (RLMD) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-24 | 개시 | Piper Sandler | Overweight |
| 2026-01-23 | 재개 | Leerink Partners | Outperform |
| 2025-12-22 | 개시 | Jefferies | Buy |
| 2025-11-19 | 업그레이드 | Mizuho | Neutral → Outperform |
| 2024-12-05 | 다운그레이드 | Mizuho | Outperform → Neutral |
| 2024-09-17 | 업그레이드 | Jefferies | Hold → Buy |
| 2024-06-05 | 다운그레이드 | Goldman | Neutral → Sell |
| 2022-10-14 | 다운그레이드 | Goldman | Buy → Neutral |
| 2022-10-14 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2022-10-14 | 다운그레이드 | Truist | Buy → Hold |
| 2022-10-13 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2021-11-18 | 개시 | Mizuho | Buy |
| 2021-05-20 | 재개 | Goldman | Buy |
| 2020-10-28 | 다운그레이드 | Goldman | Buy → Neutral |
| 2020-07-14 | 개시 | Oppenheimer | Outperform |
| 2020-05-04 | 개시 | SunTrust | Buy |
| 2020-04-21 | 개시 | Goldman | Buy |
| 2020-01-27 | 개시 | Jefferies | Buy |
| 2020-01-10 | 개시 | SVB Leerink | Outperform |
| 2019-12-16 | 개시 | Guggenheim | Buy |
모두보기
Relmada Therapeutics Inc 주식(RLMD)의 최신 뉴스
Relmada Therapeutics Inc (RLMD) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Relmada Therapeutics Inc (RLMD) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
RLMD|Relmada Therapeutics Inc|Price:5.180|Chg%:-0.020 - TradingKey
Relmada Therapeutics Inc Revenue Breakdown – FWB:4E2 - TradingView
Relmada Therapeutics Inc (RLMD) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Relmada Therapeutics Inc (RLMD) Institutional Confidence - TradingKey
Relmada Therapeutics schedules Q2 2026 financial results call - Bitget
Relmada Therapeutics to Report Second Quarter 2026 Financial Results on Thursday, August 6, 2026 - Investing News Network
Relmada Therapeutics to announce Q2 2026 financial results - scanx.trade
Mizuho Securities Maintains Relmada Therapeutics(RLMD.US) With Buy Rating, Maintains Target Price $19 - Moomoo
RELMADA THERAPEUTICS INC (RLMD) Stock Chart - ChartMill
Relmada Therapeutics (RLMD) Short Interest & Short Float | Updated Jul 2026 - MarketBeat
Relmada Therapeutics Inc. (RLMD) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
Relmada's cancer drug candidate sparks fresh bullish call - MSN
RLMDRelmada Therapeutics Inc Options - Finviz
Relmada Therapeutics (RLMD) Faces Minor Pullback, Testing Key Support LevelsAAII Bullish - dars.gov.et
RLMD Q1 2026 Earnings: Reported Loss Exceeds Expectations, Stock DropsDiluted EPS Report - DonanımHaber
Enterprise value to EBITDA forward of Relmada Therapeutics, Inc. – NASDAQ:RLMD - TradingView
Enterprise value to revenue forward of Relmada Therapeutics, Inc. – NASDAQ:RLMD - TradingView
Price to book forward of Relmada Therapeutics, Inc. – NASDAQ:RLMD - TradingView
Relmada Therapeutics, Inc.(NasdaqCM:RLMD) added to Russell Small Cap Comp Growth Benchmark - marketscreener.com
Relmada Therapeutics, Inc.(NasdaqCM: RLMD) added to Russell 2500 Growth Benchmark - marketscreener.com
Relmada Therapeutics Joins Russell 2000, Russell 3000 Indexes - marketscreener.com
Relmada Therapeutics, Inc.(NasdaqCM: RLMD) added to Russell 2000 Index - marketscreener.com
Relmada Therapeutics added to Russell 2000 and 3000 indexes - Investing.com
Relmada Therapeutics added to Russell 2000 and 3000 indexes By Investing.com - Investing.com Australia
Relmada Therapeutics (RLMD) Joins Russell 2000 and 3000 Indices - GuruFocus
Relmada Therapeutics Joins Russell 2000® and Russell 3000® Indexes - GlobeNewswire
Relmada Therapeutics, Inc.(NasdaqCM: RLMD) added to Russell 2000 Growth Benchmark - marketscreener.com
Price to earnings forward of Relmada Therapeutics, Inc. – NASDAQ:RLMD - TradingView
Relmada Therapeutics, Inc.(NasdaqCM: RLMD) added to Russell 3000E Index - marketscreener.com
Price to sales forward of Relmada Therapeutics, Inc. – NASDAQ:RLMD - TradingView
Relmada Therapeutics, Inc.(NasdaqCM: RLMD) added to Russell Microcap Index - marketscreener.com
Relmada Therapeutics, Inc.(NasdaqCM:RLMD) added to Russell Microcap Growth Benchmark Index - marketscreener.com
Relmada Therapeutics, Inc.(NasdaqCM: RLMD) added to Russell 3000 Growth Benchmark - marketscreener.com
RLMD Jumps As HC Wainwright Launches Buy Coverage - timothysykes.com
RLMD Jumps As H.C. Wainwright Launches Bullish Coverage - timothysykes.com
Relmada Therapeutics Inc Actuals & Estimates (NASDAQ:RLMD) - TradingView
RLMD Forecast — Price Target — Prediction for 2027 - TradingView
4E2 Forecast — Price Target — Prediction for 2027 - TradingView
RLMD Q1 2026 Earnings: EPS Miss as Stock Edges Higher on Pipeline FocusEPS Estimate Trend - dars.gov.et
Relmada Therapeutics Inc (NASDAQ: RLMD) Share Price, RLMD Stock News, RLMD Share Price & Updates - Kalkine
Relmada Therapeutics stock maintained at Buy by H.C. Wainwright - Investing.com
H.C. Wainwright Maintains Relmada Therapeutics(RLMD.US) With Buy Rating, Maintains Target Price $12 - Moomoo
H.C. Wainwright Reiterates Buy Rating on Relmada Therapeutics Inc (RLMD) - StreetInsider
Form 13G Relmada Therapeutics For: 22 June By Investing.com - Investing.com Australia
Millennium Group reports 4.57M Relmada shares (NASDAQ: RLMD) in 13G - Stock Titan
Relmada Therapeutics, Inc.(NasdaqCM:RLMD) added to S&P Pharmaceuticals Select Industry Index - marketscreener.com
Relmada Therapeutics Inc (RLMD) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.97%
0.83%
자본화:
|
볼륨(24시간):